drugset

drugset / Trial / NCT04241276

A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer

NCT04241276 ↗

Phase 2 Active not recruiting 170 enrolled Queen Mary University of London Celgene Corporation · collab Medical Research Council · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, multi-centre, randomised, stratified, phase IIb clinical trial of ATRA administered in combination with gemcitabine and nab-paclitaxel in patients with laPDAC.

Timeline

Start: 2020-04-30
Primary completion: 2028-06-29
Completion: 2029-02-28

Publications

Kocher HM; BCI-STARPAC2 team; BPTB team; Precision-Panc team; Sasieni P, Corrie P, McNamara MG, Sarker D, Froeling FEM, Christie A, Gillmore R, Khan K, Propper D. Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. BMC Cancer. 2025 Jan 20;25(1):106. doi: 10.1186/s12885-024-13333-z.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tretinoin	Small molecule	45 mg/m2	Oral
Background	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Background	Paclitaxel	Small molecule	125 mg/m2	Intravenous

Indications